Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 31998R2728

    Commission Regulation (EC) No 2728/98 of 17 December 1998 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance)

    SL L 343, 18.12.1998, p. 8–11 (ES, DA, DE, EL, EN, FR, IT, NL, PT, FI, SV)

    Ovaj dokument objavljen je u određenim posebnim izdanjima (CS, ET, LV, LT, HU, MT, PL, SK, SL, BG, RO)

    Legal status of the document No longer in force, Date of end of validity: 05/07/2009; Implicitno stavljeno izvan snage 32009R0470

    ELI: http://data.europa.eu/eli/reg/1998/2728/oj

    18.12.1998   

    EN

    Official Journal of the European Communities

    L 343/8


    COMMISSION REGULATION (EC) No 2728/98

    of 17 December 1998

    amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin

    (Text with EEA relevance)

    THE COMMISSION OF THE EUROPEAN COMMUNITIES,

    Having regard to the Treaty establishing the European Community,

    Having regard to Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (1), as last amended by Commission Regulation (EC) No 2692/98 (2), and in particular Articles 6, 7 and 8 thereof,

    Whereas, in accordance with Regulation (EEC) No 2377/90, maximum residue limits must be established progressively for all pharmacologically active substances which are used within the Community in veterinary medicinal products intended for administration to food-producing animals;

    Whereas maximum residue limits should be established only after the examination within the Committee for Veterinary Medicinal Products of all the relevant information concerning the safety of residues of the substance concerned for the consumer of foodstuffs of animal origin and the impact of residues on the industrial processing of foodstuffs;

    Whereas, in establishing maximum residue limits for residues of veterinary medicinal products in foodstuffs of animal origin, it is necessary to specify the animal species in which residues may be present, the levels which may be present in each of the relevant meat tissues obtained from the treated animal (target tissue) and the nature of the residue which is relevant for the monitoring of residues (marker residue);

    Whereas, for the control of residues, as provided for in appropriate Community legislation, maximum residue limits should usually be established for the target tissues of liver or kidney; whereas, however, the liver and kidney are frequently removed from carcases moving in international trade, and maximum residue limits should therefore also always be established for muscle or fat tissues;

    Whereas, in the case of veterinary medicinal products intended for use in laying birds, lactating animals or honey bees, maximum residue limits must also be established for eggs, milk or honey;

    Whereas enrofloxacin and ivermectin should be inserted into Annex I to Regulation (EEC) No 2377/90;

    Whereas hyperici oleum, eucalypti aetheroleum, sodium 2-methyl-2-phenoxy-propanoate, nonivamide, nicoboxil, methyl nicotinate, mecillinam, 8-hydroxyquinoline and diethylene glycol monoethyl ether should be inserted into Annex II to Regulation (EEC) No 2377/90;

    Whereas, in order to allow for the completion of scientific studies, the duration of the validity of the provisional maximum residue limits previously defined in Annex III to Regulation (EEC) No 2377/90 should be extended for enrofloxacin;

    Whereas a period of 60 days should be allowed before the entry into force of this Regulation in order to allow Member States to make any adjustment which may be necessary to the authorisations to place the veterinary medicinal products concerned on the market which have been granted in accordance with Council Directive 81/851/EEC (3), as last amended by Directive 93/40/EEC (4), to take account of the provisions of this Regulation;

    Whereas the measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products,

    HAS ADOPTED THIS REGULATION:

    Article 1

    Annexes I, II and III to Regulation (EEC) No 2377/90 are hereby amended as set out in the Annex hereto.

    Article 2

    This Regulation shall enter into force on the 60th day following its publication in the Official Journal of the European Communities.

    This Regulation shall be binding in its entirety and directly applicable in all Member States.

    Done at Brussels, 17 December 1998.

    For the Commission

    Martin BANGEMANN

    Member of the Commission


    (1)  OJ L 224, 18. 8. 1990, p. 1.

    (2)  OJ L 338, 15. 12. 1998, p. 5.

    (3)  OJ L 317, 6. 11. 1981, p. 1.

    (4)  OJ L 214, 24. 8. 1993, p. 31.


    ANNEX

    A.

    Annex I to Regulation (EEC) No 2377/90 is amended as follows:

    1.

    Anti-infectious agents

    1.2.

    Antibiotics

    1.2.3.

    Quinolones

    Pharmacologically active substance(s)

    Marker residue

    Animal species

    MRLs

    Target tissues

    Other provisions

    Enrofloxacin

    Sum of enrofloxacin and ciprofloxacin

    Bovine

    100 μg/kg

    Muscle

     

    100 μg/kg

    Fat

    300 μg/kg

    Liver

    200 μg/kg

    Kidney

    100 μg/kg

    Milk

    Rabbits

    100 μg/kg

    Muscle

    100 μg/kg

    Fat

    200 μg/kg

    Liver

    300 μg/kg

    Kidney

    Porcine

    100 μg/kg

    Muscle

    100 μg/kg

    Skin + fat

    200 μg/kg

    Liver

    300 μg/kg

    Kidney

    Poultry

    100 μg/kg

    Muscle

    Not for use in animals from which eggs are produced for human consumption

    100 μg/kg

    Skin + fat

    200 μg/kg

    Liver

    300 μg /kg

    Kidney

    2.

    Antiparasitic agents

    2.3.

    Agents acting against endo- and ectoparasites

    2.3.1.

    Avermectins

    Pharmacologically active substance(s)

    Marker residue

    Animal species

    MRLs

    Target tissues

    Other provisions

    Ivermectin

    22,23-Dihydro-aver-mectin B1a

    Deer, including reindeer

    20 μg/kg

    Muscle

     

    100 μg/kg

    Fat

    50 μg/kg

    Liver

    20 μg/kg

    Kidney

    B.

    Annex II to Regulation (EEC) No 2377/90 is amended as follows:

    2.

    Organic compounds

    Pharmacologically active substance(s)

    Animal species

    Other provisions

    8-Hydroxyquinoline

    All mammalian food producing species

    For topical use in new-born animals only

    Diethylene glycol monoethyl ether

    Bovine, porcine

     

    Mecillinam

    Bovine

    For intra-uterine use only

    Methyl nicotinate

    Bovine, equidae

    For topical use only

    Nicoboxil

    Equidae

    For topical use only

    Nonivamide

    Equidae

    For topical use only

    Sodium 2-methyl-2-phenoxy-propanoate

    Bovine, porcine, caprine, equidae

     

    6.

    Substances of vegetable origin

    Pharmacologically active substance(s)

    Animal species

    Other provisions

    Eucalypti aetheroleum

    All food producing species

     

    Hyperici oleum

    All food producing species

    For topical use only

    C.

    Annex III to Regulation (EEC) No 2377/90 is amended as follows:

    1.

    Anti-infectious agents

    1.2.

    Antibiotics

    1.2.06.

    Quinolones

    Pharmacologically active substance(s)

    Marker residue

    Animal species

    MRLs

    Target tissues

    Other provisions

    Enrofloxacin

    Sum of enrofloxacin and ciprofloxacin

    Ovine

    100 μg/kg

    Muscle

    Provisional MRLs expire on 1 July 1999

    100 μg /kg

    Fat

    300 μg/kg

    Liver

    200 μg/kg

    Kidney


    Top